Adaptive Biotechnologies Gestione
Gestione criteri di controllo 2/4
Adaptive Biotechnologies Il CEO è Chad Robins, nominato in Sep2009, e ha un mandato di 15.17 anni. la retribuzione annua totale è $ 8.90M, composta da 7.4% di stipendio e 92.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.23% delle azioni della società, per un valore di $ 10.40M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.2 anni e 8.8 anni.
Informazioni chiave
Chad Robins
Amministratore delegato
US$8.9m
Compenso totale
| Percentuale dello stipendio del CEO | 7.4% |
| Mandato del CEO | 15.2yrs |
| Proprietà del CEO | 1.2% |
| Durata media del management | 6.2yrs |
| Durata media del Consiglio di amministrazione | 8.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Adaptive Biotechnologies: Making Some Progress
Nov 26Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Nov 26
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Compensazione vs Mercato: La retribuzione totale di Chad ($USD 8.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.16M ).
Compensazione vs guadagni: La retribuzione di Chad è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Chad Robins (50 yo)
15.2yrs
Mandato
US$8,904,267
Compensazione
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.4m | |
| President & COO | 6.8yrs | US$2.97m | 0.32% $ 2.7m | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$8.61m | 0.69% $ 5.9m | |
| Chief Commercial Officer of Immune Medicine | 6.8yrs | US$2.88m | 0.22% $ 1.9m | |
| Founder | no data | Nessun dato | Nessun dato | |
| VP, CFO & Principal Accounting Officer | 3.1yrs | US$1.66m | 0.10% $ 884.3k | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief People Officer | 5.6yrs | Nessun dato | 0.17% $ 1.5m | |
| Chief Commercial Officer of MRD | 4.3yrs | Nessun dato | 0.17% $ 1.5m | |
| Senior Vice President of MRD BioPharma | 1.2yrs | Nessun dato | Nessun dato |
6.2yrs
Durata media
50yo
Età media
Gestione esperta: Il team dirigenziale di ADPT è esperto e expertise (durata media dell'incarico 6.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.4m | |
| Lead Independent Director | 10.9yrs | US$355.00k | 0.093% $ 790.6k | |
| Member of Corporate Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.7yrs | US$330.00k | 0.035% $ 297.7k | |
| Independent Director | 11.8yrs | US$325.00k | 0.051% $ 435.3k | |
| Independent Director | 6.8yrs | US$310.00k | 0.037% $ 311.1k | |
| Member of Corporate Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Corporate Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Corporate Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Corporate Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 3.7yrs | US$310.00k | 0.038% $ 321.6k |
8.8yrs
Durata media
58.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ADPT sono considerati esperti (durata media dell'incarico 8.8 anni).